Marker Therapeutics, Inc.

Monthly Archives: May 2016

TapImmune to Present at SeeThruEquity and Marcum Conferences in New York City

Home (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced it will be presenting at two financial conferences in New York City during the week of May 30 through June 3, 2016.
Read More